QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: mol.105.016741v1 69/2/509    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Perry, M. Articles by Mitcheson, J. S. Search for Related Content PubMed PubMed Citation Articles by Perry, M. Articles by Mitcheson, J. S.

Drug Binding Interactions in the Inner Cavity of hERG Channels: Molecular Insights from Structure-Activity Relationships of Clofilium and Ibutilide Analogs

Department of Cell Physiology and Pharmacology, Maurice Shock Medical Sciences Building, University of Leicester, Leicester, United Kingdom (M.P., J.S.M.); Pfizer Global Research & Development, Pfizer Limited, Sandwich, Kent, United Kingdom (J.L., C.W., M.J.d.G., D.L.); and Department of Biochemistry, University of Leicester, Leicester, United Kingdom (P.J.S., M.J.S.)

Block of human ether-a-go-go related gene (hERG) K⁺ channels by otherwise useful drugs is the most common cause of long QT syndrome, a disorder of cardiac repolarization that predisposes patients to potentially fatal arrhythmias. This undesirable long QT side effect has been a major reason for the withdrawal of medications from the pharmaceutical market. Understanding the molecular basis of hERG block is therefore essential to facilitate the design of safe drugs. Binding sites for hERG blockers have been mapped within the inner cavity of the channel and include aromatic residues in the S6 helix (Tyr-652, Phe-656) and residues in the pore helix (Thr-623, Ser-624, Val-625). We used mutagenesis of these residues, combined with an investigation of hERG block by close analogs of clofilium and ibutilide, to assess how specific alterations in drug structure affected potency and binding interactions. Although changing the basic nitrogen from quaternary to tertiary accelerated the onset of block, the IC₅₀ and kinetics for recovery from block were similar. In contrast, analogs with different para-substituents on the phenyl ring had significantly different potencies for wild-type hERG block. The highest potency was achieved with polar or electronegative para-substituents, whereas neutral para-substituents had potencies more than 100-fold lower. Results from mutagenesis and molecular modeling studies suggest that phenyl ring para-substituents influence drug interactions with Thr-623, Ser-624, and Tyr-652 and strongly affect binding affinity. Together, these findings suggest that modifying the para-substituent could be a useful strategy for reducing hERG potency and increasing the safety margin of compounds in development.

Address correspondence to: John Mitcheson, University of Leicester, Department of Cell Physiology and Pharmacology, Maurice Shock Medical Sciences Building, University Road, Leicester, LE1 9HN, United Kingdom. E-mail: jm109{at}le.ac.uk

This article has been cited by other articles:

				R. M. Hardman, P. J. Stansfeld, S. Dalibalta, M. J. Sutcliffe, and J. S. Mitcheson Activation Gating of hERG Potassium Channels: S6 GLYCINES ARE NOT REQUIRED AS GATING HINGES J. Biol. Chem., November 2, 2007; 282(44): 31972 - 31981. [Abstract] [Full Text] [PDF]

				K. Kamiya, R. Niwa, J. S. Mitcheson, and M. C. Sanguinetti Molecular Determinants of hERG Channel Block Mol. Pharmacol., May 1, 2006; 69(5): 1709 - 1716. [Abstract] [Full Text] [PDF]